1	HOUSE OF REPRESENTATIVES - FLOOR VERSION
2	STATE OF OKLAHOMA
3	1st Session of the 59th Legislature (2023)
4	HOUSE BILL 2748 By: Miller and Conley of the House
5	and
6	
7	Stanley of the Senate
8	
9	AS INTRODUCED
10	An Act relating to public health and safety;
11	prohibiting step therapy requirements for certain drugs for certain conditions; providing definitions;
12	authorizing a health benefit plan to allow coverage for prescription drugs for advanced metastatic cancer
13	and associated conditions without proving step therapy; and providing an effective date.
14	
15	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
16	SECTION 1. NEW LAW A new section of law to be codified
17	in the Oklahoma Statutes as Section 7320 of Title 63, unless there
18	is created a duplication in numbering, reads as follows:
19	For the purpose of prohibiting step therapy requirements for
20	certain prescription drugs to treat advanced metastatic cancer and
21	associated conditions.
22	As used in this section:
23	1. "Associated conditions" means the symptoms or side effects
24	associated with advanced metastatic cancer or its treatment and

which, in the judgment of the health care practitioner, will further
jeopardize the health of a patient if left untreated;

3 2. "Advanced metastatic cancer" means cancer that has spread
4 from the primary or original site of the cancer to nearby tissues,
5 lymph nodes, or other areas or parts of the body.

6 SECTION 2. NEW LAW A new section of law to be codified 7 in the Oklahoma Statutes as Section 7321 of Title 63, unless there 8 is created a duplication in numbering, reads as follows:

9 A. A health benefit plan that provides coverage for advanced 10 metastatic cancer and associated conditions may not require, before 11 the health benefit plan provides coverage of a prescription drug 12 approved by the United States Food and Drug Administration, that the 13 enrollee:

14 1. Fails to successfully respond to a different drug; or 15 2. Proves a history of failure of a different drug. 16 This section applies only to a drug, the use of which is: Β. 17 1. Consistent with best practices for the treatment of advanced 18 metastatic cancer or an associated condition; 19 Supported by peer-reviewed, evidence-based literature; and 2.

20
3. Approved by the United States Food and Drug Administration.
21
21 SECTION 3. This act shall become effective November 1, 2023.
22

23 COMMITTEE REPORT BY: COMMITTEE ON INSURANCE, dated 02/28/2023 - DO PASS, As Coauthored.

24